Pasithea Therapeutics Corp (KTTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pasithea Therapeutics Corp (KTTA) has a cash flow conversion efficiency ratio of -0.237x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.89 Million) by net assets ($12.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Pasithea Therapeutics Corp (KTTA) market capitalisation for the company's overall valuation and market capitalisation.
Pasithea Therapeutics Corp - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Pasithea Therapeutics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pasithea Therapeutics Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pasithea Therapeutics Corp ranked by their cash flow conversion efficiency. Explore Pasithea Therapeutics Corp earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cahayaputra Asa Keramik Tbk PT
JK:CAKK
|
0.138x |
|
Nam Sung
KO:004270
|
-0.009x |
|
Pinnacle Food Group Limited Class A Common Shares
NASDAQ:PFAI
|
N/A |
|
Pets at Home Group Plc
LSE:PETS
|
0.086x |
|
ECSTELECOM Co. Ltd
KQ:067010
|
0.056x |
|
IRIDEX Corporation
NASDAQ:IRIX
|
0.048x |
|
Miliboo SA
PA:ALMLB
|
0.126x |
|
Gaming Corps AB
ST:GCOR
|
0.791x |
Annual Cash Flow Conversion Efficiency for Pasithea Therapeutics Corp (2020–2024)
The table below shows the annual cash flow conversion efficiency of Pasithea Therapeutics Corp from 2020 to 2024. View Pasithea Therapeutics Corp stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $14.78 Million | $-13.92 Million | -0.942x | -64.15% |
| 2023-12-31 | $23.40 Million | $-13.43 Million | -0.574x | -78.10% |
| 2022-12-31 | $42.50 Million | $-13.69 Million | -0.322x | -421.90% |
| 2021-12-31 | $51.42 Million | $-3.17 Million | -0.062x | +61.49% |
| 2020-12-31 | $241.35K | $-38.69K | -0.160x | -- |
About Pasithea Therapeutics Corp
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1);… Read more